Insinga Ralph P, Dasbach Erik J, Elbasha Elamin H
Department of Health Economic Statistics, Merck Research Laboratories, North Wales, PA, USA.
BMC Infect Dis. 2009 Jul 29;9:119. doi: 10.1186/1471-2334-9-119.
Natural history models of human papillomavirus (HPV) infection and disease have been used in a number of policy evaluations of technologies to prevent and screen for HPV disease (e.g., cervical cancer, anogenital warts), sometimes with wide variation in values for epidemiologic and clinical inputs. The objectives of this study are to: (1) Provide an updated critical and systematic review of the evidence base to support epidemiologic and clinical modeling of key HPV disease-related parameters in the context of an HPV multi-type disease transmission model which we have applied within a U.S. population context; (2) Identify areas where additional studies are particularly needed.
Consistent with our and other prior HPV natural history models, the literature review was confined to cervical disease and genital warts. Between October 2005 and January 2006, data were gathered from the published English language medical literature through a search of the PubMed database and references were examined from prior HPV natural history models and review papers. Study design and data quality from individual studies were compared and analyses meeting pre-defined criteria were selected.
Published data meeting review eligibility criteria were most plentiful for natural history parameters relating to the progression and regression of cervical intraepithelial neoplasia (CIN) without HPV typing, and data concerning the natural history of HPV disease due to specific HPV types were often lacking. Epidemiologic evidence to support age-dependency in the risk of progression and regression of HPV disease was found to be weak, and an alternative hypothesis concerning the time-dependence of transition rates is explored. No data were found on the duration of immunity following HPV infection. In the area of clinical management, data were observed to be lacking on the proportion of clinically manifest anogenital warts that are treated and the proportion of cervical cancer cases that become symptomatic by stage.
Knowledge of the natural history of HPV disease has been considerably enhanced over the past two decades, through the publication of an increasing number of relevant studies. However, considerable opportunity remains for advancing our understanding of HPV natural history and the quality of associated models, particularly with respect to examining HPV age- and type-specific outcomes, and acquired immunity following infection.
人乳头瘤病毒(HPV)感染及疾病的自然史模型已被用于多项预防和筛查HPV疾病(如宫颈癌、肛门生殖器疣)技术的政策评估中,有时流行病学和临床输入值差异很大。本研究的目的是:(1)对证据基础进行更新的批判性和系统性综述,以支持在美国人群背景下应用的HPV多型疾病传播模型中关键HPV疾病相关参数的流行病学和临床建模;(2)确定特别需要进一步研究的领域。
与我们及其他先前的HPV自然史模型一致,文献综述仅限于宫颈疾病和生殖器疣。2005年10月至2006年1月期间,通过搜索PubMed数据库从已发表的英文医学文献中收集数据,并查阅先前HPV自然史模型和综述论文中的参考文献。比较了个体研究的研究设计和数据质量,并选择了符合预定义标准的分析。
符合综述入选标准的已发表数据,关于未进行HPV分型的宫颈上皮内瘤变(CIN)进展和消退的自然史参数最为丰富,而关于特定HPV类型所致HPV疾病自然史的数据往往缺乏。支持HPV疾病进展和消退风险存在年龄依赖性的流行病学证据薄弱,并探讨了关于转换率时间依赖性的另一种假设。未发现关于HPV感染后免疫持续时间的数据。在临床管理领域,观察到缺乏关于接受治疗的临床显性肛门生殖器疣比例以及宫颈癌病例按阶段出现症状比例的数据。
在过去二十年中,通过越来越多相关研究的发表,对HPV疾病自然史的了解有了显著提高。然而,在推进我们对HPV自然史及相关模型质量的理解方面仍有很大机会,特别是在研究HPV年龄和类型特异性结局以及感染后获得性免疫方面。